Science Confirms Turmeric As Effective As 14

New Post Public Reply Private Reply Replies (2) Message Board
wowhappens28
298
Science Confirms Turmeric As Effective As 14 Drugs

http://www.greenmedinfo.com/blog/science-conf...e-14-drugs

If ever there were an herb that puts existential fear into the bottom line of pharmaceutical companies, its turmeric. Here are a few thousand reasons why...

Turmeric is one the most thoroughly researched plants in existence today. Its medicinal properties and components (primarily curcumin) have been the subject of over 12,000 peer-reviewed and published biomedical studies. In fact, our five-year long research project on this sacred plant has revealed over 800 potential preventive and therapeutic applications, as well as 250 distinct beneficial physiological effects. This entire database of 2,666 ncbi-hyperlinked turmeric abstracts can be downloaded as a PDF at our Downloadable Turmeric Document page, and acquired either as a retail item or with 1 GMI-token, for those of you who are already are members and receive them automatically each year or month, depending on your membership plan.

Given the sheer density of research performed on this remarkable spice, it is no wonder that a growing number of studies have concluded that it compares favorably to a variety of conventional medications, including:

Lipitor/Atorvastatin(cholesterol medication): A 2008 study published in the journal Drugs in R & D found that a standardized preparation of curcuminoids from Turmeric compared favorably to the drug atorvastatin (trade name Lipitor) on endothelial dysfunction, the underlying pathology of the blood vessels that drives atherosclerosis, in association with reductions in inflammation and oxidative stress in type 2 diabetic patients. [For addition curcumin and 'high cholesterol' research – 8 abstracts]
Corticosteroids (steroid medications): A 1999 study published in the journal Phytotherapy Research found that the primary polyphenol in turmeric, the saffron colored pigment known as curcumin, compared favorably to steroids in the management of chronic anterior uveitis, an inflammatory eye disease.[ii] A 2008 study published in Critical Care Medicine found that curcumin compared favorably to the corticosteroid drug dexamethasone in the animal model as an alternative therapy for protecting lung transplantation-associated injury by down-regulating inflammatory genes.[iii] An earlier 2003 study published in Cancer Letters found the same drug also compared favorably to dexamethasone in a lung ischaemia-repurfusion injury model.[iv] [for additional curcumin and inflammation research – 52 abstracts]
Prozac/Fluoxetine & Imipramine (antidepressants): A 2011 study published in the journal Acta Poloniae Pharmaceutica found that curcumin compared favorably to both drugs in reducing depressive behavior in an animal model.[v] [for additional curcumin and depression research – 5 abstracts]
Aspirin (blood thinner): A 1986 in vitro and ex vivo study published in the journal Arzneimittelforschung found that curcumin has anti-platelet and prostacyclin modulating effects compared to aspirin, indicating it may have value in patients prone to vascular thrombosis and requiring anti-arthritis therapy.[vi] [for additional curcumin and anti-platelet research]
Anti-inflammatory Drugs: A 2004 study published in the journal Oncogene found that curcumin (as well as resveratrol) were effective alternatives to the drugs aspirin, ibuprofen, sulindac, phenylbutazone, naproxen, indomethacin, diclofenac, dexamethasone, celecoxib, and tamoxifen in exerting anti-inflammatory and anti-proliferative activity against tumor cells.[vii] [for additional curcumin and anti-proliferative research – 15 abstracts]
Oxaliplatin (chemotherapy drug): A 2007 study published in the International Journal of Cancer found that curcumin compares favorably with oxaliplatin as an antiproliferative agenet in colorectal cell lines.[viii] [for additional curcumin and colorectal cancer research – 52 abstracts]
Metformin (diabetes drug): A 2009 study published in the journal Biochemitry and Biophysical Research Community explored how curcumin might be valuable in treating diabetes, finding that it activates AMPK (which increases glucose uptake) and suppresses gluconeogenic gene expression (which suppresses glucose production in the liver) in hepatoma cells. Interestingly, they found curcumin to be 500 times to 100,000 times (in the form known as tetrahydrocurcuminoids(THC)) more potent than metformin in activating AMPK and its downstream target acetyl-CoA carboxylase (ACC).[ix]
Another way in which turmeric and its components reveal their remarkable therapeutic properties is in research on drug resistant- and multi-drug resistant cancers. We have two sections on our site dedicated to researching natural and integrative therapies on these topics, and while there are dozens of substances with demonstrable efficacy against these chemotherapy- and radiation-resistant cancers, curcumin tops both lists:

Cancers: Drug Resistant
Cancers: Multi-Drug Resistant
We have found no less than 97 studies indicating that curcumin can induce cell death or sensitize drug-resistant cancer cell lines to conventional treatment. View them here. [x]

We have identified 28 studies on curcumin's ability to either induce cell death or sensitize multi-drug resistant cancer cell lines to conventional treatment. View them here. [xi]

Considering how strong a track record turmeric (curcumin) has, having been used as both food and medicine in a wide range of cultures, for thousands of years, a strong argument can be made for using curcumin as a drug alternative or adjuvant in cancer treatment.

Or, better yet, use certified organic (non-irradiated) turmeric in lower culinary doses on a daily basis so that heroic doses won't be necessary later in life after a serious disease sets in. Nourishing yourself, rather than self-medicating with 'nutraceuticals,' should be the goal of a healthy diet.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Dahua's Pro Challenge 2026: Bridging Expertise Globally

Updated Category News Views 64

Celebrating Global Installer Expertise Dahua Technology took to the stage in Hangzhou for the Pro Challenge 2026, a shindig pulling installer partners from every corner of the globe. This wasn't just a tech jamboree; it was a tip of the hat to those on the ground who make Dahua's AIoT solutions tick. You know the drill: hands-on demos, tech showcases, and a whole lot of...

Continue Reading
Data Center Transformers on the Brink of a Boom

Updated Category News Views 235

A Flash Look: Powering Up Data Centers Look, if you're thinking of sidestepping data center transformers as just another cog in the machine, think again. This market's set to balloon—doubling from $5.59 billion in 2026 to a jaw-dropping $10.72 billion by 2031. We're talking a chunky 13.9% CAGR. Not every bit of news grabs you by the lapels, but this one does. What’s...

Continue Reading
Parallels Desktop: Top Dog for Windows on Mac

Updated Category News Views 75

A Simpler Way to Bridge the Mac and Windows World Seems like Parallels Desktop is once again flexing its muscles for Mac users in 2026. Expert Consumers out of New York just gave them the thumbs-up as the go-to pick for folks wanting to hitch their Mac wagon to Windows 11. And why not? Parallels lets you take a stroll through Windows land without cutting your Mac ties. A...

Continue Reading
WeFetch AI: A New Era in Barcode Precision

Updated Category News Views 46

WeFetch AI: What's in a Name? Forget about GreenCore Solutions Corp. We're talking about WeFetch AI Corp. now. They've just changed their name, fulfilling a bureaucratic tick as of November 13, 2026. But it ain't just a name change; it's a whole new ballgame in AI-driven commerce. AI Shopping Without the Guesswork We've all been there. You think you've ordered that...

Continue Reading
Greenworks Mower Snags Best Electric Award for 2026

Updated Category News Views 41

Greenworks Strikes Again with Top Lawn Mower Honors Man, when I think about the evolution from noisy, gas-guzzling lawn mowers to sleek, battery-powered beasts, Greenworks is right there, leading the charge. Just the other day, Popular Mechanics singled out the Greenworks 80V 22-inch Cordless Lawn Mower, handing it the coveted title of Best Electric Lawn Mower for 2026....

Continue Reading
ACME's AI Innovation Shakes Up Filmmaking Scene

Updated Category News Views 26

The Game-Changer in Virtual Production You ever hear about the Grey Box™ phenomenon? Sounds like a sci-fi gizmo, right? Turns out, it's the real deal and ACME Media's been riding this revolutionary wave straight to the top of the film industry ladder. Their approach with this AI-driven gizmo isn't just about cutting-edge tech wizardry—it's reimagining how we shoot...

Continue Reading
PangeAI and Sky Blue Transform Data Center Decisions

Updated Category News Views 80

Just when you thought the incessant trials of picking a prime data center site couldn’t get any more grueling or expensive, enter PangeAI and its brand-new ally, Sky Blue Impact. These tech firms have partnered up to speed up what has traditionally been a sluggish, pricey process. Here’s the deal: PangeAI’s geospatial AI platform lets Sky Blue dodge the usually...

Continue Reading
Decoding Arrest: Steps from Arraignment to Trial

Updated Category News Views 71

Someone lands in handcuffs, and it's the start of a winding road through the justice system. We're talking about the stages you gotta navigate, explained by Criminal Law Attorney Tangi Carter. If you're anywhere near Hattiesburg, Mississippi, or quite frankly, have any eye on legal matters in your backyard, you know having a roadmap is pure gold. Arraignment: The...

Continue Reading
Millrose Faces Investor Deadline in Class Action Lawsuit

Updated Category News Views 75

Shakeup at Millrose Properties: Investor Alert! Alright, folks, gather around. We got a situation brewing with Millrose Properties, Inc. (NYSE: MRP) that's catching the attention of anyone who's hauled their portfolio through the storms and sunshine of the stock market. A class action lawsuit's knocking at the door, and any daydreaming investor who snatched up shares...

Continue Reading
AppLovin Faces Serious Investor Lawsuit Deadline

Updated Category News Views 72

Investors' Trust Shaken: The AppLovin Controversy Well, what do we have here? Another day, another hefty lawsuit coming down the pike. The spotlight’s on AppLovin Corporation (NASDAQ: APP), where the Hagens Berman law sharks are sniffing blood in the water over what they claim are federal securities law violations. The core of this legal storm swirls around AppLovin's...

Continue Reading

Top 5 Most Recently Viewed Articles

Global Polymer Foam Market Trends and Insights for 2025-2034

Updated Category News Views 255

Understanding the Polymer Foam Market The polymer foam market has witnessed significant growth recently, with a valuation of USD 151.19 billion in 2024 and expectations of reaching USD 273.58 billion by 2034. This growth corresponds to a compound annual growth rate (CAGR) of 6.11% from 2025 to 2034. A substantial portion of this expansion is influenced by the increasing...

Continue Reading
Renee Gala Takes the Helm as Jazz Pharmaceuticals CEO

Updated Category News Views 249

Renee Gala Takes on Leadership at Jazz Pharmaceuticals In an exciting development for Jazz Pharmaceuticals, the Board of Directors has announced the unanimous selection of Renee Gala as the new President and Chief Executive Officer. This pivotal decision is set to take effect shortly, marking a significant transition for the company as it continues to forge its path in...

Continue Reading
Finzly Launches AI Security Layer Amid Rising Threats

Updated Category News Views 58

Bank Security in the Age of AI You'd think banks, of all places, were impenetrable fortresses. But these days, they're more like digital targets. With AI-driven attacks becoming as common as morning coffee, Finzly's introducing Assure, an AI-powered security and assurance layer. It's about as timely as ever, given the 89% spike in AI-enabled attacks seen last year. When...

Continue Reading
Fidelity National Financial Launches New Consent Solicitation

Updated Category News Views 304

Introduction to Consent Solicitation Fidelity National Financial, Inc. (NYSE: FNF) has recently announced the commencement of separate consent solicitations for its various series of Senior Notes, an initiative that aims to amend the terms of its existing indenture agreements. The company holds four series of Senior Notes—4.500% due in 2028, 3.400% due in 2030, 2.450%...

Continue Reading
Legal Insights on Hims & Hers Health, Inc. Class Action Case

Updated Category News Views 179

Understanding the Hims & Hers Health, Inc. Securities Litigation The legal landscape surrounding Hims & Hers Health, Inc. has become a focal point for investors as the recent securities fraud lawsuit unfolds. Investors have an opportunity to engage in this case, which may hold significant implications for their investments. Why This Lawsuit Matters This lawsuit,...

Continue Reading